HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
2008

Gene Therapy for EBV-Associated Cancer

publication Evidence: moderate

Author Information

Author(s): Lifang Yang, Min Tang, Midan Ai, Ya Cao

Primary Institution: Molecular Biology Research Center, Cancer Research Institute, XiangYa School of Medicine, Central South University

Hypothesis

Can gene therapy using HSV-tk/GCV effectively treat Epstein-Barr virus (EBV)-associated cancer?

Conclusion

The pVLTR-tk/GCV suicide gene system may be used as a new gene targeting strategy for EBV-associated cancer.

Supporting Evidence

  • The pVLTR-tk/GCV system showed significant cytotoxic effects on EBV-LMP1 positive cancer cells.
  • A bystander effect was observed, where non-transfected cells were also affected by the treatment.
  • The treatment induced apoptosis in LMP1 positive cells.
  • Tumor growth was significantly suppressed in vivo with the pVLTR-tk/GCV treatment.

Takeaway

This study shows that a special gene therapy can help kill cancer cells caused by a virus called EBV.

Methodology

The study involved constructing a plasmid and testing its effects on cancer cells using various assays and animal experiments.

Limitations

The study did not investigate the toxic effects of pVLTR-tk/GCV genes in normal tissues.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-9966-27-42

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication